TCI Wealth Advisors’s Pacira BioSciences PCRX Stock Holding History

TCI Wealth Advisors’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-43	Closed	-$1.66K	–	2606
2022 Q4	$1.66K	Hold	43	–	–	﹤0.01%	2015
2022 Q3	$2K	Sell	43 -155	-78%	-$8.62K	﹤0.01%	1968
2022 Q2	$12K	Hold	198	–	–	﹤0.01%	912
2022 Q1	$15K	Hold	198	–	–	﹤0.01%	840
2021 Q4	$12K	Buy	198 +90	+83%	+$4.96K	﹤0.01%	1043
2021 Q3	$6K	Buy	108 +22	+26%	+$1.27K	﹤0.01%	1491
2021 Q2	$5K	Buy	86 +14	+19%	+$886	﹤0.01%	1468
2021 Q1	$5K	Buy	72 +29	+67%	+$2.07K	﹤0.01%	1291
2020 Q4	$3K	Hold	43	–	–	﹤0.01%	1119
2020 Q3	$3K	Hold	43	–	–	﹤0.01%	985
2020 Q2	$2K	Buy	+43	New	+$1.8K	﹤0.01%	1096
2020 Q1	–	Sell	-43	Closed	-$2K	–	1686
2019 Q4	$2K	Buy	+43	New	+$1.83K	﹤0.01%	1179

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

TCI Wealth Advisors's PCRX Position: Q1 2023 in Review

TCI Wealth Advisors sold out of Pacira BioSciences (PCRX) in Q1 2023, closing a stake of 43 shares — an estimated $1.66K sold.

TCI Wealth Advisors first reported a position in PCRX in Q4 2019 and held it in 12 quarters. The position peaked at $15K in Q1 2022. 267 funds tracked by Wall St. Rank hold PCRX as of Q1 2023.

TCI Wealth Advisors reported no remaining Pacira BioSciences position as of Q1 2023 after selling out during the quarter.
TCI Wealth Advisors sold 43 Pacira BioSciences shares in Q1 2023, an estimated $1.66K.
TCI Wealth Advisors first reported a position in Pacira BioSciences in Q4 2019 and held it in 12 quarters.
TCI Wealth Advisors's Pacira BioSciences position peaked at $15K in Q1 2022.
267 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2023.

Based on TCI Wealth Advisors's 13F filing for Q1 2023, filed 3 May 2023.